Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety

A technology of Glycosin A and Glycosine, which is applied to the application field of Gycosin A, Glycosine, and 1-methoxycryphrine in the preparation of medicines for treating anxiety disorders, and can solve problems such as uninvolved, etc., Achieve no tolerance, expand the safe treatment window, and achieve the effect of less side effects

Active Publication Date: 2011-11-16
FUJIAN MEDICAL UNIV
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing research on the activity of kinesin alkaloid monomers does not involve the research on its anti-anxiety eff

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Inhibitory effects of coxomorphine A, coxomorphin and 1-methoxycphrine on the anxiety behavior of elevated plus maze in mice by subcutaneous injection on the back of the neck.

[0041] 1.1 Drugs and Reagents:

[0042] Glycosin A, Glycosine, and 1-methoxycyphrine were obtained by the applicant of the present invention by extracting, separating and purifying from the natural plant G. japonica, and the purity was >98.5% (accurately weighing G. Methoxychamnosine was dissolved in 1 mol / l HCl, diluted with normal saline, adjusted to pH with 1 mol / l NaOH (4

[0043] 1.2 Animals:

[0044] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. The animals were reared under a light-dark cycle of 12 / 12 h at room temperature at 25°C, with...

Embodiment 2

[0058] Inhibitory effects of coxomorphine A, coxomorphin, and 1-methoxycphrine on the anxiety behavior of light and dark boxes in mice by subcutaneous injection on the back of the neck.

[0059] 2.1 Drugs and Reagents:

[0060] Glycosin A, Glycosine, and 1-methoxycyphrine were obtained by the applicant of the present invention by extracting, separating and purifying from the natural plant G. japonica, and the purity was >98.5% (accurately weighing G. Methoxychamnosine was dissolved in 1 mol / l HCl, diluted with normal saline, adjusted to pH with 1 mol / l NaOH (4

[0061] 2.2 Animals:

[0062] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. The animals were reared under a light-dark cycle of 12 / 12 h at room temperature at 25°C, w...

Embodiment 3

[0076] Experiment on the median lethal dose of total alkaloids, arginine A, glucosamine and 1-methoxy argonine by subcutaneous injection on the back of the neck of mice

[0077] 2.1 Drugs and Reagents:

[0078] The total alkaloids of Gonchospermia, Glycosin A, Glycosin A, 1-methoxycrysphrine were obtained by the applicant of the present invention by extracting, separating and purifying from the natural plant G. archaea, and the purity was more than 98.5% (accurately weighing Glycosin A, Glycosin and 1-methoxycryphrine were dissolved in 1 mol / l HCl, diluted with normal saline, adjusted to pH (4

[0079] 2.2 Animals:

[0080] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. The animals were reared under a light-dark cycle of 12 / 12 h at room temperature at 25°C, with free food, and adapted to the laboratory for 3 days ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of gelsemine, koumine and 1-methoxyl gelsemine to the preparation of a medicine for treating the anxiety, especially an application of gelsemium alkaloid monomer gelsemine as the sole active ingredient or a pharmaceutically acceptable salt thereof to the preparation of the medicine for treating the anxiety, an application of gelsemium alkaloid monomer koumine as the sole active ingredient or the pharmaceutically acceptable salt thereof to the preparation of the medicine for treating the anxiety, and an application of gelsemium alkaloid monomer 1-methoxyl gelsemine as the sole active ingredient or the pharmaceutically acceptable salt thereof to the preparation of the medicine for treating the anxiety; and the gelsemine, the koumine and the 1-methoxyl gelsemine can play significant roles in treating the murine anxiety in far below the toxic dose so that the safe therapeutic window is remarkable expanded, have no tolerance, low addiction and side effect, and are more suitable for the preparation of the medicine for treating the anxiety in comparison with gelsemium total alkaloids.

Description

technical field [0001] The present invention relates to the application of gelsemine alkaloid monomers, in particular to the application of gelsemine A (Gelsemine), gelsemine seed (Koumine) and 1-methoxygelsemine in the preparation of drugs for treating anxiety. Background technique [0002] Anxiety disorder, also known as anxiety neurosis, is a common disease, which can be divided into two types: panic disorder and generalized anxiety according to clinical manifestations. According to relevant reports in the United States, more than 490 million people worldwide suffer from anxiety disorders, and the lifetime prevalence rate among the population is 5%; the prevalence rate reported in China has reached 2% to 3%. If anxiety disorders are left untreated for a long time, 40% to 50% of patients may develop into depression. Anti-anxiety drugs are currently one of the main means of clinically treating patients' anxiety disorders. A research report entitled "Anti-Anxiety: Strategic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61P25/22
Inventor 俞昌喜刘铭许盈苏燕评杨渐
Owner FUJIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap